Literature DB >> 32189446

Simulation in Urological Training and Education (SIMULATE): Protocol and curriculum development of the first multicentre international randomized controlled trial assessing the transferability of simulation-based surgical training.

Abdullatif Aydin1, Kamran Ahmed1,2, Mieke Van Hemelrijck3, Hashim U Ahmed4,5, Muhammad Shamim Khan1,6, Prokar Dasgupta1,6.   

Abstract

OBJECTIVES: To report the study protocol for the first international multicentre randomized controlled trial investigating the effectiveness of simulation-based surgical training and the development process for an evidence-based training curriculum, to be delivered as an educational intervention. PARTICIPANTS AND METHODS: This prospective, international, multicentre randomized controlled clinical and educational trial will recruit urology surgical trainees who must not have performed ≥10 of the selected index procedure, ureterorenoscopy (URS). Participants will be randomized to simulation-based training (SBT) or non-simulation-based training (NSBT), the latter of which is the current sole standard of training globally. The primary outcome is the number of procedures required to achieve proficiency, where proficiency is defined as achieving a learning curve plateau of 28 or more on an Objective Structured Assessment of Technical Skills (OSATS) assessment scale, for three consecutive operations, without any complications. All participants will be followed up either until they complete 25 procedures or for 18 months. Development of the URS SBT curriculum took place through a two-round Delphi process.
RESULTS: A total of 47 respondents, consisting of trainees (n = 24) with URS experience and urolithiasis specialists (n = 23), participated in round 1 of the Delphi process. Specialists (n = 10) finalized the content of the curriculum in round 2. The developed interventional curriculum consists of initial theoretic knowledge through didactic lectures followed by select tasks and cases on the URO-Mentor (Simbionix, Lod, Israel) VR Simulator, Uro-Scopic Trainer (Limbs & Things, Bristol, UK) and Scope Trainer (Mediskills, Manchester, UK) models for both semi-rigid and flexible URS. Respondents also selected relevant non-technical skills scenarios and cadaveric simulation tasks as additional components, with delivery subject to local availability.
CONCLUSIONS: SIMULATE is the first multicentre trial investigating the effect and transferability of supplementary SBT on operating performance and patient outcomes. An evidence-based training curriculum is presented, developed with expert and trainee input. Participants will be followed and the primary outcome, number of procedures required to proficiency, will be reported alongside key clinical secondary outcomes, (ISCRTN 12260261).
© 2020 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International.

Entities:  

Keywords:  ISCRTN 12260261; randomised controlled trial; simulation; surgery; training; urology

Mesh:

Year:  2020        PMID: 32189446     DOI: 10.1111/bju.15056

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.969


  3 in total

Review 1.  Innovations in Urologic Surgical Training.

Authors:  Runzhuo Ma; Sharath Reddy; Erik B Vanstrum; Andrew J Hung
Journal:  Curr Urol Rep       Date:  2021-03-13       Impact factor: 3.092

2.  Slowdown of urology residents' learning curve during the COVID-19 emergency.

Authors:  Francesco Porpiglia; Enrico Checcucci; Daniele Amparore; Paolo Verri; Riccardo Campi; Francesco Claps; Franceso Esperto; Cristian Fiori; Giuseppe Carrieri; Vincenzo Ficarra; Roberto Mario Scarpa; Prokar Dasgupta
Journal:  BJU Int       Date:  2020-04-28       Impact factor: 5.588

3.  The SIMULATE ureteroscopy training curriculum: educational value and transfer of skills.

Authors:  Abdullatif Aydın; Kamran Ahmed; Umair Baig; Nicholas Raison; Andrea G Lantz Powers; Nicola Macchione; Ahmed Al-Jabir; Takashige Abe; Muhammad Shamim Khan; Prokar Dasgupta
Journal:  World J Urol       Date:  2021-02-03       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.